EDTA Chelation from RevitaLife Compounding Pharmacy

Available through:

EDTA Chelation

Available Dosage Strengths
EDTA, Vitamin C, B-Complex, Procaine, Magnesium

EDTA combined with Procaine, vitamins (C, B-complex), magnesium, and trace minerals intended for heavy-metal chelation under medical supervision.

  • Chelates certain metals (lead, cadmium; limited evidence for others)
  • Supports antioxidant pathways
  • EDTA: binds divalent and trivalent metals for renal excretion.
  • Vitamin C +: Provides antioxidant support during chelation.
  • Procaine: Known for its chelating properties, aids in the removal of heavy metals from tissues and organs, supporting overall detoxification.
  • Low calcium levels (EDTA)
  • Kidney strain
  • Nausea, hypotension
  • Nephrotoxicity: Edetate CALCIUM disodium is potentially nephrotoxic. Renal tubular acidosis and fatal nephrosis may occur.

These intravenous infusions should not be administered to patients with:

  • Chronic renal insufficiency
  • Congestive heart failure
  • Atrial fibrillation, and known allergies on vitamins, minerals, and related substances. and other ingredients contained in the IV infusion bag.
  • This should not be administered to patients below 18 years old.
  • EDTA is contradicted for those who have active renal disease or anuria; hepatitis.
  • Pregnancy & breastfeeding.
  • Kidney disease
  • Hypocalcemia
  • Increased renal clearance of some metals and minerals
  • Drug Interactions: Digoxin, diuretics, potassium-depleting medicines. If the patient is taking any medicine, check first for any possible drug interaction before use. Do not take alcohol, sleep aids, or tranquilizers of other CNS depressants.
  • EDTA x Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic).
  • EDTA x Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.
  • EDTA x Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased.
  • EDTA x BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical).

These are general categories of references typically supporting nutrient-based IV therapy mechanisms:

  1. Modern Nutrition in Health and Disease, 12th Ed.
  2. NIH Office of Dietary Supplements – Fact Sheets (Vitamin C, B12, Magnesium, Zinc, etc.)
  3. European Food Safety Authority (EFSA) scientific opinions on micronutrients
  4. PubMed-indexed reviews on IV vitamin therapy, antioxidant therapy, NAC, glutathione, and EDTA chelation
  5. Drug–nutrient interaction data from Lexicomp & Micromedex

Related Medications

Get in Touch

Contact Us To Get Better Information

Scroll to Top